Option Care Health, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This annual filing reports full-year results; separate fourth-quarter financial results are not clearly provided in the filing text.
Business context
Option Care Health provides home and alternate-site infusion services through 177 locations in 43 states, including 93 pharmacies and 84 ambulatory infusion suites. It operates as one infusion-services segment. Revenue is primarily from commercial and government third-party payers for pharmaceuticals and related clinical services.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change / context |
|---|---|---|---|
| Revenue | $4,302.3 million | $3,944.7 million | Up 9.1% |
| Gross profit / margin | $981.2 million / 22.8% | $866.9 million / 22.0% | Gross profit up 13.2%; margin expanded 0.8 percentage points |
| Operating income / margin | $314.6 million / 7.3% | $240.2 million / 6.1% | Margin expanded 1.2 percentage points |
| Net income | $267.1 million | $150.6 million | Up 77.4%; 2023 includes a material Amedisys termination-related benefit |
| Diluted EPS | $1.48 | $0.83 | 2023 includes the termination-related benefit |
| Operating cash flow | $371.3 million | $267.5 million | Up $103.7 million |
| Cash and cash equivalents | $343.8 million | $294.2 million | At December 31 |
| Debt principal | $1,088.0 million | $1,094.0 million | $588.0 million term loan and $500.0 million senior notes |
Investing cash outflow was $56.5 million, including $41.9 million of property and equipment purchases and $12.5 million for an acquisition. Financing cash outflow was $265.1 million, primarily reflecting $250.3 million of share repurchases. At year-end, the company had $394.7 million of net availability under its new $400 million revolving facility, after letters of credit. Management said cash, expected operating cash flows, and planned capital expenditures should support operating requirements for at least the next 12 months and beyond.
The term loan bears a variable rate; its year-end rate was 8.21%. The $500 million senior notes carry a 4.375% coupon and mature in 2029. A $300 million interest-rate cap partially hedges variable-rate exposure; management estimated that a 100-basis-point change in unhedged rates would change annual interest expense by approximately $2.9 million.
Material changes versus 2022
- Revenue growth reflected organic expansion: chronic therapies grew at a low-double-digit rate and acute therapies at a mid-single-digit rate. Growth was partly offset by the 2022 respiratory-therapy asset sale and reduced revenue from ALS and pre-term-labor therapies.
- Gross margin improved as revenue grew faster than costs, which the company attributed partly to procurement discipline, favorable temporary therapy-pricing dynamics, and efficient workforce and infusion-suite utilization.
- Operating cash flow rose, supported by higher net income and the Amedisys termination payment, among other items; cash used in investing fell mainly because acquisition spending declined.
- Other income included the Amedisys termination payment, while 2022 other income included a $10.3 million pretax gain on the respiratory-therapy asset sale.
- The company terminated its proposed Amedisys merger in June 2023 and received a $106 million payment. It recorded $21.1 million of merger-related expenses; the payment net of related expenses and taxes contributed $63.1 million to 2023 net income.
- The company repurchased approximately $250 million of stock during 2023 and increased its authorization to $500 million, leaving $250 million authorized at year-end. It also replaced its asset-based revolving facility with a $400 million revolving facility in December.
Outlook, risks, and unusual items
The filing provides no quantitative 2024 revenue, earnings, or cash-flow guidance. Management emphasized continued investment in pharmacies, infusion suites, and information technology, and described acquisitions as part of its growth strategy.
- Reimbursement and pricing: The business depends on payer relationships and negotiated reimbursement; pricing pressure, benchmark changes, delayed collections, audits, or government payment reductions could affect margins, cash flow, and liquidity. Approximately 88% of revenue came from nongovernmental payers, 12% from direct government programs, and the largest payer accounted for about 14%.
- Supply and concentration: Four vendors represented approximately 72% of pharmaceutical and medical-supply purchases. Drug shortages, restricted distribution, or loss of manufacturer relationships could disrupt service or profitability.
- Labor and operations: Shortages of nurses, pharmacists, and other clinicians may raise costs or limit service capacity. Inflation, competition, and changes in therapy mix also pose risks.
- Regulation and liability: The company operates under extensive pharmacy, compounding, healthcare reimbursement, privacy, and fraud-and-abuse requirements. It faces potential payer disputes, legal proceedings, and professional-liability claims; management did not expect pending matters, after reserves and indemnification, to materially affect the balance sheet, while acknowledging outcomes could be adverse.
- Leverage and interest rates: Debt service, covenants, variable-rate exposure, and potential refinancing needs could constrain investment or liquidity.
- Other notable disclosures: Goodwill was approximately $1.54 billion; the company reported no goodwill impairment in 2023. The auditor’s critical audit matter concerned evidence supporting estimates of transaction-price adjustments. KPMG gave unqualified opinions on the financial statements and internal control over financial reporting.
Most important facts for investors to verify
- How much of reported revenue and earnings growth is recurring, excluding the $63.1 million after-tax Amedisys termination-related contribution and other unusual items?
- Whether gross-margin improvement persists as temporary favorable pricing dynamics change and payer reimbursement and drug acquisition costs reset.
- Cash conversion and working-capital trends, including inventory growth, receivables, and collection timing.
- Debt repayment capacity and interest-rate sensitivity, including the term-loan rate, revolving-facility use, and covenant headroom.
- Progress and returns from the remaining $250 million share-repurchase authorization, alongside capital expenditure and acquisition needs.
- Exposure to major payers and suppliers, drug shortages, regulatory changes, and clinician staffing constraints.